We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RGA:NYSEReinsurance Group of America, Incorporated Analysis

Data as of 2026-08-03 - not real-time

$236.85

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Reinsurance Group of America (RGA) is trading at $236.85, comfortably above its 20‑day ($235.67), 50‑day ($219.23) and 200‑day ($206.59) simple moving averages, signaling a sustained bullish trend. The stock’s RSI sits at 58.6, indicating modest momentum without being overbought, while the MACD histogram is slightly negative, suggesting a short‑term bearish tilt but not enough to offset the broader uptrend. Volatility remains elevated at roughly 24% over the past 30 days, yet the beta of 0.30 points to low systematic risk relative to the market. Fundamentally, RGA delivers a compelling value story: a trailing P/E of 12.9 versus an industry average of 18.0, a forward P/E of just 8.1, and a price‑to‑book of 1.17, all implying the stock is undervalued. Revenue growth is robust at 23.5% YoY, with Q1 sales up 21.6% to $6.49 bn, and EPS is projected to jump from $18.40 trailing to $29.25 forward, underscoring strong earnings momentum. The dividend yield of 1.57% coupled with a modest 20% payout ratio supports a sustainable income stream. Recent accolades—including being named “Reinsurer of the Year” – and a refreshed leadership team reinforce confidence in execution, while analysts collectively rate the stock as a “Buy” with a median target of $269, implying roughly 10% upside.
Given the combination of technical strength, attractive valuation metrics, solid growth, and a low‑beta profile, RGA presents a balanced risk‑reward proposition. The upside potential is modest but credible, and the dividend adds a defensive layer. However, the elevated short‑term volatility and a bearish MACD signal suggest caution on immediate entries, though the broader fundamentals remain resilient.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 8/10

Key Factors

  • Price above key moving averages indicating bullish momentum
  • Upcoming earnings release with recent Q1 beat
  • Technical support at $220.33 and modest upside potential

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued valuation metrics (P/E, forward P/E) relative to peers
  • Strong revenue and EPS growth outlook
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Diversified global reinsurance footprint reducing concentration risk
  • Award‑winning market position and leadership stability
  • Low beta and solid balance sheet supporting resilience

Key Metrics & Analysis

Financial Health

Revenue Growth23.50%
Profit Margin4.92%
P/E Ratio12.9
ROE9.90%
ROA0.85%
Debt/Equity45.61
P/B Ratio1.2
Op. Cash Flow$5.5B
Free Cash Flow$4.8B
Industry P/E18.0

Technical Analysis

TrendBullish
RSI58.6
Support$220.33
Resistance$245.00
MA 20$235.67
MA 50$219.23
MA 200$206.59
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

Fair Value$2,420.46
Target Price$261.78
Upside/Downside10.52%
GradeUndervalued
TypeBlend
Dividend Yield1.57%

Risk Assessment

Beta0.30
Volatility23.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.